Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$74.55 USD
+0.53 (0.72%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $74.61 +0.06 (0.08%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Price, Consensus and EPS Surprise
RDY 74.55 +0.53(0.72%)
Will RDY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RDY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RDY
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
RDY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Here's Why Doctor Reddy's (RDY) is a Strong Value Stock
Other News for RDY
RDY Crosses Above Average Analyst Target
Dr. Reddy’s Forges Nutraceuticals JV; Leadership Changes
Nestlé and Dr. Reddy’s Forge Nutraceuticals JV
Dr. Reddy’s Announces Urgent Medication Recall
Dr. Reddy’s Faces USFDA Hurdle for Biosimilar